127 related articles for article (PubMed ID: 35642291)
1. Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials.
Chen R; Basu S; Meyers JP; Shi Q
Stat Methods Med Res; 2022 Oct; 31(10):1819-1844. PubMed ID: 35642291
[TBL] [Abstract][Full Text] [Related]
2. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
3. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
[TBL] [Abstract][Full Text] [Related]
4. Design and analysis of non-inferiority mortality trials in oncology.
Rothmann M; Li N; Chen G; Chi GY; Temple R; Tsou HH
Stat Med; 2003 Jan; 22(2):239-64. PubMed ID: 12520560
[TBL] [Abstract][Full Text] [Related]
5. Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study.
Parpia S; Thabane L; Julian JA; Whelan TJ; Levine MN
BMC Med Res Methodol; 2013 Mar; 13():44. PubMed ID: 23517401
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
7. Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards.
Möllenhoff K; Tresch A
Lifetime Data Anal; 2023 Jul; 29(3):483-507. PubMed ID: 36708450
[TBL] [Abstract][Full Text] [Related]
8. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
9. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation.
Quartagno M; Walker AS; Babiker AG; Turner RM; Parmar MKB; Copas A; White IR
Trials; 2020 Feb; 21(1):145. PubMed ID: 32029000
[TBL] [Abstract][Full Text] [Related]
10. Impact of disinvestment from weekend allied health services across acute medical and surgical wards: 2 stepped-wedge cluster randomised controlled trials.
Haines TP; Bowles KA; Mitchell D; O'Brien L; Markham D; Plumb S; May K; Philip K; Haas R; Sarkies MN; Ghaly M; Shackell M; Chiu T; McPhail S; McDermott F; Skinner EH
PLoS Med; 2017 Oct; 14(10):e1002412. PubMed ID: 29088237
[TBL] [Abstract][Full Text] [Related]
11. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review.
Althunian TA; de Boer A; Klungel OH; Insani WN; Groenwold RH
Trials; 2017 Mar; 18(1):107. PubMed ID: 28270184
[TBL] [Abstract][Full Text] [Related]
12. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
13. A note on the determination of non-inferiority margins with application in oncology clinical trials.
Yu B; Yang H; Sabin A
Contemp Clin Trials Commun; 2019 Dec; 16():100454. PubMed ID: 31650074
[TBL] [Abstract][Full Text] [Related]
14. Non-inferiority test for a continuous variable with a flexible margin in an active controlled trial: an application to the "Stratall ANRS 12110 / ESTHER" trial.
Sandie AB; Molinari N; Wanjoya A; Kouanfack C; Laurent C; Tchatchueng-Mbougua JB
Trials; 2022 Mar; 23(1):202. PubMed ID: 35248123
[TBL] [Abstract][Full Text] [Related]
15. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
Royston P; Parmar MK
BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based sizing of non-inferiority trials using decision models.
Lansdorp-Vogelaar I; Jagsi R; Jayasekera J; Stout NK; Mitchell SA; Feuer EJ
BMC Med Res Methodol; 2019 Jan; 19(1):3. PubMed ID: 30612554
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
18. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
19. Adjusting for unknown bias in non-inferiority clinical trials.
Odem-Davis K; Fleming TR
Stat Biopharm Res; 2013 Jan; 5(3):. PubMed ID: 24187607
[TBL] [Abstract][Full Text] [Related]
20. Study duration for three-arm non-inferiority survival trials designed for accrual by cohorts.
Wu Y; Li Y; Hou Y; Li K; Zhou X
Stat Methods Med Res; 2018 Feb; 27(2):507-520. PubMed ID: 26994213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
